Navigation Links
ActivBiotics Proposes Development Strategy for Its Novel Rifamycin Antibiotics

WELLESLEY HILLS, Mass., Feb. 25 /PRNewswire/ -- Joseph F. Finn, Jr., CPA, the Assignee for the Benefit of Creditors of ActivBiotics, as a result of growing interest from prospective buyers, announced today a development strategy for further advancement of the company's proprietary benzoxazinorifamycins as leading antibacterial drug candidates in combination antibiotic therapy. Rifalazil is the most developed of these compounds, though most of the interest for combination antibiotics has centered on novel compounds or new chemical entities ("NCEs").

Combination antibiotic therapy has been used as the treatment of choice for certain stubborn bacterial infections. Two prime examples are tuberculosis and gastric ulcer disease, caused by Mycobacterium tuberculosis infection and Helicobacter pylori infection, respectively. In both of these examples, the rifamycins rifampin and rifabutin have been used because of their potency against these pathogens. However, these rifamycins share the negative attribute of eliciting drug-drug interactions; that is, they interfere with the actions of many other medications that the patient may require. The NCEs are breakthrough drug candidates because they have not been shown preclinically to engender drug-drug interactions caused by the other rifamycins. In addition the NCEs have equal or superior potency compared with rifampin.

There is increasing recognition that rifamycins (e.g. rifampin and ABI- 0043) are highly efficacious against implant-associated staphylococcal infection. This property is due to their excellent efficacy against non- growing and surface-adhering staphylococci. No other class of antimicrobial agents shares this property. In view of the growing number of patients with implants (artificial joints, internal fixation devices, vascular grafts etc.) there is an urgent need for this type of antibiotic. "The development of an NCE for combination antibiotic treatment could be extremely beneficial," commented Werner Zimmerli, M.D., a leading infectious disease clinician and researcher at the University of Basel, Switzerland. "In our animal model for implant-associated infections, which has proven to be clinically predictive of combination antibiotic efficacy for the treatment of foreign body infections, the NCE ABI-0043 was as effective as rifampin. The fact that ABI-0043 is not predicted to have drug-drug interactions provides a very significant advantage over rifampin, which cannot be given, for example, in patients with oral anticoagulation due to dangerous interaction." In addition, based on their antibacterial spectrum and potency against key pathogens, the NCEs may also be developed for the treatment of bacterial endocarditis, osteomyelitis, acute and chronic respiratory infections, gastrointestinal infections, and acne.

The sale of ActivBiotics' assets, including rifalazil and the NCEs, is being conducted through an Assignment for the Benefit of Creditors. The bidding for the assets, which may be purchased separately or in combination, is scheduled for March 14, 2008.

For additional information on the terms of sale and to obtain a bidder's package, please contact Joseph F. Finn, Jr., CPA (, phone 781-237-8840), Finn, Warnke & Gayton, 167 Worcester Street, Suite 201, Wellesley Hills, MA 02481-3613. For technical information on the assets, please contact Christo Shalish,

SOURCE ActivBiotics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. ActivBiotics Outlines a Clinical Path Forward to Examine if Rifalazil Is Superior to Azithromycin in the Treatment of Chlamydia STD
2. ActivBiotics Receives Orphan Drug Designation from the European Medicines Agency for Superoxide Dismutase Mimetic, M40403, in Oral Mucositis Indication
3. ActivBiotics to Present Results of Pivotal Study in the Treatment of Peripheral Arterial Disease at AHA Meeting
4. Cancer Cure Coalition Proposes Major Changes at the FDA
5. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
6. Immtech Focusing on Other Infectious Disease Programs Following Discontinuation of Development of Pafuramidine
7. Bionovo Announces Positive Developments in On-going Phase 1/2 Cancer Drug Trial
8. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
9. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
10. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
11. Pharmacopeia Nominates Novel Chemokine Receptor Antagonist for Development
Post Your Comments:
(Date:11/25/2015)... , November 25, 2015 - Will ... Medical Education (CME) --> - Will ... Continuing Medical Education (CME) --> ... Continuing Medical Education (CME) ... products and services, will feature latest diagnostic imaging textbooks and decision ...
(Date:11/25/2015)... DUBLIN , Nov. 25, 2015 Research ... of the "Membranes Market - Global Forecast to ... Asia-Pacific , accounting for 37.21% of the ... Asia-Pacific region is projected to ... This growth has been attributed primarily to the fast ...
(Date:11/25/2015)... 2015 --> ... Lizenz für das Patent über eine neue Hepatitis-B-Behandlung, welches ... innehaben, an Enyo Pharma vergeben haben. Im ... gerufenen und von Edelris gemeinsam mit seinen Partnern Inserm ... für HBV identifiziert, und es wurden neue Inhaltsstoffe entdeckt, ...
Breaking Medicine Technology:
(Date:11/24/2015)... ... November 24, 2015 , ... American Family Care (AFC), the ... of a holiday pop-up clinic located in Metro Atlanta’s North Point Mall. The clinic ... and different way. The location is scheduled to operate through Dec. 24. , Holiday ...
(Date:11/24/2015)... Danbury, CT (PRWEB) , ... November 24, 2015 , ... ... Network (WCHN) today announced an innovative study designed to yield insights into how to ... potential development of biomarkers for pancreatic cancer from small, non-coding RNA molecules (ncRNA), genetic ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... Cleveland University-Kansas City (CU-KC), in Overland Park, Kansas. Benson, a fifth-trimester ... University President Carl S. Cleveland III on October 16. , “Katie is very ...
(Date:11/24/2015)... ... November 24, 2015 , ... American Specialty ... Program have announced their endorsement of the Medical Fitness Network (MFN), a ... proud to have the MFN as one of our endorsed organizations,” said ASH ...
(Date:11/24/2015)... ... ... Dr. Kevin Day, local family chiropractor in Warsaw , is hosting a ... During the Indiana winter months, Vitamin D deficiency can lead to Seasonal Affective Disorder ... help provide the tools needed to combat it this year! , “Stress kills us,” ...
Breaking Medicine News(10 mins):